News

CRISPR/Cas9 Industry News

Statements and background on the CRISPR patent landscape

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to…
ERS Genomics and genOway Enter CRISPR/Cas9 Agreement
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…
Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent
Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third Arguments filed in opposition to JP6692856 rejected JP2019-210828 represents third Japanese patent   Dublin,…

Questions and answers about CRISPR patents

CVC’s issued patents are to the composition and use of the core type 2 CRISPR/Cas9 complex to modify DNA in ANY ENVIRONMENT without limitation to uses in eukaryotic cells. CVC further has issued patents on single guide RNA (sgRNA) which greatly enhances the efficiency of CRISPR gene editing in many applications.

In the United States, Broad’s issued patents (currently subject to a PTAB initiated interference) are for certain methods of genome editing and uses only in eukaryotic cells. 

In December, 2012, Broad requested “accelerated examination” of its application. This meant the USPTO considered the application more quickly. CVC did not request accelerated examination when it applied for a patent in May, 2012.

CRISPR research is a large field that involves contributions from many talented scientists around the world. The USPTO had issued more than 570 patents as of September 2020, with claims to CRISPR and/or Cas9 to approximately 900 inventors from more than 200 applicant organizations. The European Patent Office (EPO) had issued more than 190 such patents to more than 460 inventors from about 110 applicant institutions. In addition, there have been more than 9,200 applications filed (and published but not yet granted) around the world.

Current CVC patent list can be viewed here.

Over the next several years, there will be many more patents issued in the CRISPR field, to many inventors from many institutions, in recognition of each individual’s contribution to advancing CRISPR technology.

Latest news

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement

License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology   DUBLIN, Ireland and Coralville, Iowa, 17 August 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Cellular Engineering Technologies (CET), a biotechnology company specializing in cell manufacturing and contract research services, today announced a non-exclusive license agreement granting CET access to ERS Genomics’ CRISPR/Cas9 patent portfolio. With its expertise in cell and tissue engineering, CET supports research organizations at the interface of stem cell research and preclinical

Read more